Lisdexamfetamine for treatment of attention-deficit/hyperactivity disorder

Annals of Pharmacotherapy

Volumn 43, Issue 4, 2009, Pages 669-676

  Cowles, Brian J ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Attention deficit hyperactivity disorder; Lisdexamfetamine

Indexed keywords

AMPHETAMINE; DECONGESTIVE AGENT; DEXAMPHETAMINE; LISDEXAMFETAMINE; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; PLACEBO; TRICYCLIC ANTIDEPRESSANT AGENT;

AGITATION; ANOREXIA; ANXIETY; AREA UNDER THE CURVE; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DECREASED APPETITE; DRUG ABUSE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG LABELING; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG TRANSFORMATION; DRUG WITHDRAWAL; DYSTONIA; GROUPS BY AGE; GROWTH DISORDER; HALLUCINATION; HEART ARRHYTHMIA; HUMAN; INSOMNIA; IRRITABILITY; LD 50; MORNING DOSAGE; NERVOUSNESS; NONHUMAN; PATHOGENESIS; PATIENT COUNSELING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECOMMENDED DRUG DOSE; REVIEW; SCORING SYSTEM; SIDE EFFECT; SUDDEN DEATH; TACHYCARDIA; THORAX PAIN; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VASCULAR HEADACHE; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DEXTROAMPHETAMINE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SLEEP INITIATION AND MAINTENANCE DISORDERS; TACHYCARDIA;

EID: 65749107327     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L521     Document Type: Review

References (30)

1. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46:894-921.
2. Pliszka SR, Crismon ML, Hughes CW, et al. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45:642-657
3. Medori R, Ramos-Quiroga JA, Casas M, et al. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2008;63:981-989
4. Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr 2006;11:625-639 (Pubitemid 44253518)
5. Hoffman B. Adrenocepter-activating and other sympathomimetic drugs. In: Katzung B, ed. Basic and clinical pharmacology. New York: Lange Medical Books/McGraw Hill, 2007:121-140
6. Westfall T, Westfall D. Adrenergic agonists and antagonists. In: Brunton L, ed. Goodman and Gillman's the pharmacologic basis of therapeutics. New York: McGraw Hill Companies, Inc., 2006:237-295
7. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998;94:127-152 (Pubitemid 28352470)
8. Advokat C. Update on amphetamine neurotoxicity and its relevance to the treatment of ADHD. J Atten Disord 2007;11:8-16.
9. Krishnan S, Montcrief S. Toxicity profile of lisdexamfetamine dimesylate in three independent rat toxicology studies. Basic Clin Pharmacol Toxicol 2007;101:231-240 (Pubitemid 350194801)
10. Package insert. Vyvanse (lisdexamfetamine dimesylate). Wayne, PA: Shire Pharmaceuticals, April 2008.
11. Jasinski DR, Krishnan S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol Epub 17 Jul 2008. DOI 10.1177/0269881108093841
12. Krishnan SM, Stark JG. Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. Curr Med Res Opin 2008;24:33-40.
13. Biederman J, Boellner SW, Childress A, Lopez FA, Krishnan S, Zhang Y. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 2007;62:970-976 (Pubitemid 47562371)
14. Krishnan S, Zhang Y. Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study. J Clin Pharmacol 2008;48:293-302.
15. Clausen SB, Read SC, Tulloch SJ. Single- and multiple-dose pharmacokinetics of an oral mixed amphetamine salts extended-release formulation in adults. CNS Spectr 2005;10(suppl 20):6-15. (Pubitemid 43010493)
16. Wigal SB, Gupta S, Guinta D, Swanson JM. Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol Bull 1998;34:47-53. (Pubitemid 28176301)
17. Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther 2007;29:450-463 (Pubitemid 46924786)
18. Faries DE, Yalcin I, Harder D, Heiligenstein JH. Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Atten Disord 2001;5:107-115 (Pubitemid 33794656)
19. Findling RL, Childress AC, Krishnan S, McGough JJ. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. CNS Spectr 2008;13:614-620
20. Adler L, Goodman D, Kollins SH, et al. Efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. Presented at: 54th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Boston, October 23-28, 2007.
21. Spiller HA, Griffith JR, Anderson DL, Weber JA, Aleguas A. Poison centers detect an unexpectedly frequent number of adverse drug reactions to lisdexamfetamine (letter). Ann Pharmacother 2008;42:1142-1143
22. Krishnan S, Moncrief S. An evaluation of the cytochrome p450 inhibition potential of lisdexamfetamine in human liver microsomes. Drug Metab Dispos 2007;35:180-184 (Pubitemid 46036490)
23. Shire Pharmaceutical Development. Efficacy and safety of LDX in adolescents with attention-deficit/hyperactivity disorder (ADHD). http://clinicaltrials.gov/show/NCT00735371 (accessed 2008 Oct 25).
24. Red book drug topics. Montvale, NJ: Thomson Healthcare, 2008.
25. Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 2008;117:2407-2423
26. Perrin JM, Friedman RA, Knilans TK. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics 2008;122:451-453
27. Pliszka SR, Matthews TL, Braslow KJ, Watson MA. Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45:520-526 (Pubitemid 43756181)
28. Swanson JM, Elliott GR, Greenhill LL, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry 2007;46:1015-1027
29. Schedules of controlled substances: placement of lisdexamfetamine into schedule II. Final rule. Fed Reg 2007;72:24532-24534
30. Package insert. Concerta (methylphenidate hydrochloride). Titusville, NJ: Ortho-McNeil-Janssen, Inc., 2008 June.